CR8603A - Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos - Google Patents
Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitosInfo
- Publication number
- CR8603A CR8603A CR8603A CR8603A CR8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- compound
- mastocyt
- triptase
- aminometil
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940122598 Tryptase inhibitor Drugs 0.000 abstract 2
- 239000002750 tryptase inhibitor Substances 0.000 abstract 2
- 102000001400 Tryptase Human genes 0.000 abstract 1
- 108060005989 Tryptase Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica que comprende una cantidad farmaceuticamente eficaz del compuesto de formula I, y un vehiculo farmaceuticamente aceptable. Ademas, la presente invencion se refiere al uso de un compuesto de formula I como inhibidor de triptasa, que comprende introducir el compuesto en una composicion que comprende triptasa. Ademas la presente invencion se refiere al uso de un compuesto de formula I para tratar a un paciente que padece o propenso a padecer una afeccion fisiologica que necesita la mejora de un inhibidor de triptasa que comprende administrar al paciente una cantidad terapeuticamente eficaz del compuuesto de la reivindicacion I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692704P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8603A true CR8603A (es) | 2007-06-08 |
Family
ID=34964263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8603A CR8603A (es) | 2004-03-26 | 2006-09-07 | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070142435A1 (es) |
| EP (1) | EP1737848A1 (es) |
| JP (1) | JP2007530580A (es) |
| KR (1) | KR20060130682A (es) |
| CN (1) | CN1956978A (es) |
| AR (1) | AR048336A1 (es) |
| AU (1) | AU2005230934A1 (es) |
| BR (1) | BRPI0509245A (es) |
| CA (1) | CA2560649A1 (es) |
| CR (1) | CR8603A (es) |
| DO (1) | DOP2005000039A (es) |
| EC (1) | ECSP066878A (es) |
| IL (1) | IL178031A0 (es) |
| MA (1) | MA28547B1 (es) |
| MX (1) | MXPA06010610A (es) |
| NO (1) | NO20064811L (es) |
| PA (1) | PA8627601A1 (es) |
| PE (1) | PE20060084A1 (es) |
| RU (1) | RU2330034C1 (es) |
| TN (1) | TNSN06278A1 (es) |
| TW (1) | TW200602035A (es) |
| UA (1) | UA83738C2 (es) |
| UY (1) | UY28821A1 (es) |
| WO (1) | WO2005097780A1 (es) |
| ZA (1) | ZA200607752B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
| AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
| WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
| AR065858A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona. |
| AR065859A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Ester de 2,5-dioxo-pirrolidin-1-ilo de acido 4-bromo-3-metil-5-propoxitiofen-2- carboxilico ,su sintesis regioespecifica y un intermedio del mismo |
| US8158792B2 (en) | 2007-11-21 | 2012-04-17 | Janssen Pharmaceutica N.V. | Spiropiperidines for use as tryptase inhibitors |
| NZ587119A (en) * | 2008-01-24 | 2013-01-25 | Soligenix Inc | Use of beclomethasone dipropionate in the treatment of an interstitial lung disease |
| MX2011001135A (es) * | 2008-08-22 | 2011-03-21 | Sanofi Aventis | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-m etoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos. |
| TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
| MX2012003023A (es) * | 2009-09-24 | 2012-04-10 | Sanofi Aventis Us Llc | Sintesis del ester terc-butilico del acido (4-fluoro-3-piperidin-4 -il-bencil)-carbamico y sus productos intermedios. |
| JP2013515723A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | 炎症性腸疾患の処置 |
| RU2012131341A (ru) * | 2009-12-23 | 2014-01-27 | Санофи | Индол-пиперидинилбензиламины как ингибиторы бета-триптазы |
| JP2013515724A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類 |
| CA2790946A1 (en) * | 2010-02-24 | 2011-09-01 | Sanofi | Treatment of dermatological allergic conditions |
| HUE043171T2 (hu) | 2011-10-07 | 2019-08-28 | Takeda Pharmaceuticals Co | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek |
| CN110494453B (zh) * | 2017-02-10 | 2023-05-26 | 豪夫迈·罗氏有限公司 | 抗类胰蛋白酶抗体、其组合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5741301A (en) * | 2000-05-22 | 2001-12-03 | Aventis Pharm Prod Inc | Arylmethylamine derivatives for use as tryptase inhibitors |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en not_active Ceased
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Withdrawn
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP066878A (es) | 2006-11-24 |
| BRPI0509245A (pt) | 2007-09-11 |
| RU2330034C1 (ru) | 2008-07-27 |
| DOP2005000039A (es) | 2005-10-31 |
| EP1737848A1 (en) | 2007-01-03 |
| TNSN06278A1 (en) | 2007-12-03 |
| MA28547B1 (fr) | 2007-04-03 |
| TW200602035A (en) | 2006-01-16 |
| MXPA06010610A (es) | 2006-12-15 |
| IL178031A0 (en) | 2006-12-31 |
| JP2007530580A (ja) | 2007-11-01 |
| UA83738C2 (en) | 2008-08-11 |
| PE20060084A1 (es) | 2006-03-09 |
| CA2560649A1 (en) | 2005-10-20 |
| WO2005097780A1 (en) | 2005-10-20 |
| UY28821A1 (es) | 2005-10-31 |
| CN1956978A (zh) | 2007-05-02 |
| AU2005230934A1 (en) | 2005-10-20 |
| KR20060130682A (ko) | 2006-12-19 |
| RU2006137717A (ru) | 2008-05-10 |
| NO20064811L (no) | 2006-10-23 |
| PA8627601A1 (es) | 2006-01-23 |
| US20070142435A1 (en) | 2007-06-21 |
| AR048336A1 (es) | 2006-04-19 |
| ZA200607752B (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8603A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CR9348A (es) | Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer | |
| DE60332629D1 (de) | Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| UA104148C2 (ru) | [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| MY156278A (en) | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | |
| WO2006108682A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents | |
| SE0000303D0 (sv) | Novel compounds | |
| DE602004022578D1 (de) | Antitumorale terpen-verbindungen | |
| BRPI0507985A (pt) | derivados de piperazina uréia para o tratamento de endometriose | |
| AR062215A1 (es) | Inhibidor de trombina activo por via oral | |
| SE0401716D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |